洞察
Insights From Our Experts
Articles
Gross-to-Net Improvement Through Holistic Revenue Enhancement
Consistent price increases have long been a staple of commercial strategy for pharmaceutical manufacturers. From this uplift in topline revenue, more sizable discounts can be provided to industry middlemen, like pharmacy benefit managers (PBMs), in order…
340B Drug Pricing: Challenges and Best Practices
Enacted in 1992, the 340B Drug Pricing Program was intended to stretch scarce federal resources and services to more eligible patients. Despite achieving this goal in many respects, it has also become notoriously difficult to…
Insurance and Benefit Design
Insurance and Benefits Design provides insight on changes in insurance and benefit design in the next three years so you can anticipate the evolving access opportunities and risks for your company’s brands. Insurance and Benefit Design…
Membership Management Challenges and Best Practices
In the pharmaceutical industry, access to pricing is primarily driven by membership.Institutions like hospitals, clinics, and pharmacies sign up as members of a Group Purchasing Organization (GPO) to be eligible to purchase products at a discounted…
Pharmaceutical Contracting from Volume to Value
Driven by skyrocketing costs, market forces are hastening the shift in the healthcare industry from volume based care (fee for service) to a value based reimbursement structure (fee for value). While the inertia of entrenched policies,…
Medicaid Drug Classification: Civil Monetary Penalties
On April 18, 2019, the “Medicaid Services Investment and Accountability Act of 2019” was signed into law, bringing with it a significant change to the oversight and management of the Medicaid Drug Rebate Program (MDRP). Effective…